on various National Academies committees, including the Clinical Research Roundtable. In the past decade his writings and lectures have focused on issues of academic values and health and science policy.
Charles Bertolami, D.D.S., D. Med. Sc., is dean of the College of Dentistry at New York University. A leader in the dental research, education, and clinical communities, he was named the 14th dean of the 142-year-old New York University College of Dentistry in 2007. Dr. Bertolami was formerly the dean of the University of California-San Francisco (UCSF) School of Dentistry; during the 12 years he served in that post, the UCSF School of Dentistry led the nation in overall NIH funding for dental schools. In addition to expanding the school’s research capacity, he also enhanced the school’s clinical and teaching programs, including renovating clinics and laboratories; implemented a new curriculum reinforcing integration of basic and clinical sciences in dental education; established and expanded joint degree programs; and established a year-long post-baccalaureate program for students from economically or educationally disadvantaged groups. Dr. Bertolami is the president-elect of the American Dental Education Association and is a former president of the American Association for Dental Research.
Thomas O. Daniel, M.D., is the president of Celgene Research. Dr. Daniel has more than two decades of medical and pharmaceutical research experience, having most recently served as the chief scientific officer at Ambryx, Inc., a biotechnology company focused on discovering and developing protein-based therapeutics. Prior to that, Dr. Daniel was vice president of research at Amgen Inc., where he served as research site head for Amgen Seattle, as inflammation therapeutic area head, and on research and development portfolio review boards. Prior to Amgen’s acquisition of Immunex, Dr. Daniel was senior vice president of discovery research at Immunex, where he consolidated and built programs in oncology and vascular biology. As president of Celgene Global Research, he is responsible for leading the discovery, preclinical, and early-stage clinical programs for Celgene worldwide. Prior to his industrial positions he was the K. M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University, and director of the Vanderbilt Center for Vascular Biology. Dr. Daniel obtained his M.D. degree from University of Texas Southwestern, trained in internal medicine at Massachusetts General Hospital, completed postdoctoral work in molecular genetics at University of Texas Southwestern, was a Howard Hughes Medical Institute associate at UCSF, and an NIH-funded investigator for 20 years at Vanderbilt. His laboratory research programs focused on cellular and receptor mechanisms regulating endothelial growth and neovascularization.
Margaret Grey, Dr.Ph.P.H., R.N., F.A.A.N. (IOM), is the dean and Annie Goodrich Professor at the Yale School of Nursing. She has been at Yale since January of 1993. Prior to assuming the deanship on September 1, 2005, she served as associate dean for scholarly affairs. She is also director of the NIH-funded Center for Self and Family Management and a related pre- and postdoctoral training program. She was the founding director of the school’s doctoral program. Previously she held progressive academic and administrative appointments at the University of Pennsylvania and Columbia University. She holds a bachelor’s degree from the University of Pittsburgh, an M.S.N. in pediatric nursing from Yale University, and a doctorate in public health and social psychology from Columbia University.
James Jackson, Ph.D. (IOM), is Daniel Katz Distinguished University Professor of Psychology at the University of Michigan at Ann Arbor and director of the Institute for Social Research (ISR). Dr. Jackson’s research efforts include carrying out a number of national surveys and one international survey of black populations focusing on issues of racial and ethnic influences on life course development; attitude change; reciprocity; social support; and coping and health. He obtained his Ph.D. in social psychology from Wayne State University. Dr. Jackson is a recognized authority on African American life, and currently has a major grant from the National Institute of Mental Health to assess the physical, emotional, mental, and economic health of a nationally representative sample of more than 4,000 Black American adults. His knowledge and understanding of issues related to the underrepresentation of minority groups in biomedical, behavioral, and clinical research will be very helpful to the committee in addressing personnel needs in these populations.
Keith Micoli, Ph.D., is the manager of the postdoctoral program and ethics program coordinator at New York University’s (NYU’s) School of Medicine. He earned his B.A. from New College of Florida in 1993 and his Ph.D. from the University of Alabama at Birmingham (UAB) in 2001, and, before moving to NYU in August 2008, was a postdoctoral fellow and instructor at UAB. He also held an appointment as adjunct assistant professor at Samford University, teaching microbiology. Keith served on the board of directors of the National Postdoctoral Association from 2003 to 2007 and was board chairman from 2005 to 2007.
John C. Wooley, Ph.D., is associate vice chancellor for research at the University of California San Diego (UCSD), an adjunct professor in pharmacology and in chemistry and biochemistry, and a strategic advisor and senior fellow of the San Diego Supercomputer Center. He received his Ph.D. degree in 1975 at the University of Chicago, working with Al Crewe and Robert Uretz in biological physics. Prior to his appointment at UCSD he was at the Department of Energy, where he served as deputy associate director in the Office of Science. In that capacity, he was responsible for biological